3.連結財務諸表及び主な注記

(1)連結財政状態計算書

 

 

 

(単位:百万円)

 

前連結会計年度末

(2024年3月31日)

 

当連結会計年度末

(2025年3月31日)

資産

 

 

 

流動資産

 

 

 

現金及び現金同等物

58,094

 

55,241

営業債権及びその他の債権

47,237

 

42,292

棚卸資産

39,111

 

42,500

その他の金融資産

10,609

 

3,244

その他の流動資産

9,232

 

6,461

流動資産合計

164,285

 

149,740

非流動資産

 

 

 

有形固定資産

33,582

 

34,531

無形資産

25,120

 

48,315

使用権資産

2,971

 

2,781

その他の金融資産

32,862

 

39,492

繰延税金資産

1,766

 

5,597

その他の非流動資産

2,817

 

3,177

非流動資産合計

99,119

 

133,897

資産合計

263,404

 

283,637

 

 

 

 

 

(単位:百万円)

 

前連結会計年度末

(2024年3月31日)

 

当連結会計年度末

(2025年3月31日)

負債及び資本

 

 

 

負債

 

 

 

流動負債

 

 

 

営業債務及びその他の債務

24,706

 

16,857

その他の金融負債

372

 

305

リース負債

1,720

 

1,348

未払法人所得税

3,594

 

4,705

その他の流動負債

6,941

 

7,100

流動負債合計

37,336

 

30,316

非流動負債

 

 

 

その他の金融負債

232

 

233

リース負債

1,152

 

1,374

退職給付に係る負債

4,090

 

4,313

その他の非流動負債

58

 

59

非流動負債合計

5,533

 

5,980

負債合計

42,870

 

36,297

資本

 

 

 

資本金

5,174

 

5,174

資本剰余金

4,445

 

4,491

利益剰余金

198,260

 

222,640

自己株式

2,480

 

2,459

その他の資本の構成要素

14,825

 

17,181

親会社の所有者に帰属する持分合計

220,224

 

247,028

非支配持分

310

 

312

資本合計

220,534

 

247,340

負債及び資本合計

263,404

 

283,637

 

E0093145160日本新薬株式会社通期第3号参考様式 [IFRS](連結)IFRStrueCTECTE2024-04-012025-03-31FY2025-03-312023-04-012024-03-312024-03-311falsefalsefalse451602023-04-012024-03-31jpigp_cor:RetainedEarningsIFRSMember451602023-04-012024-03-31jpigp_cor:TreasurySharesIFRSMember451602023-04-012024-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember451602023-04-012024-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602023-04-012024-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602023-04-012024-03-31jpigp_cor:RemeasurementsOfDefinedBenefitPlansIFRSMember451602023-04-012024-03-31jpigp_cor:NonControllingInterestsIFRSMember451602023-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602023-03-31jpigp_cor:ShareCapitalIFRSMember451602023-03-31jpigp_cor:CapitalSurplusIFRSMember451602023-03-31jpigp_cor:RetainedEarningsIFRSMember451602023-03-31jpigp_cor:TreasurySharesIFRSMember451602023-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember451602023-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602023-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602023-03-31jpigp_cor:RemeasurementsOfDefinedBenefitPlansIFRSMember451602023-03-31jpigp_cor:NonControllingInterestsIFRSMember451602023-04-012024-03-31jpigp_cor:CapitalSurplusIFRSMember451602025-05-08451602025-03-31451602024-04-012025-03-31451602024-03-31451602023-04-012024-03-31451602023-03-31451602025-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602025-03-31jpigp_cor:ShareCapitalIFRSMember451602025-03-31jpigp_cor:CapitalSurplusIFRSMember451602025-03-31jpigp_cor:RetainedEarningsIFRSMember451602025-03-31jpigp_cor:TreasurySharesIFRSMember451602025-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember451602025-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602025-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602025-03-31jpigp_cor:RemeasurementsOfDefinedBenefitPlansIFRSMember451602025-03-31jpigp_cor:NonControllingInterestsIFRSMember451602024-04-012025-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602024-04-012025-03-31jpigp_cor:ShareCapitalIFRSMember451602024-04-012025-03-31jpigp_cor:CapitalSurplusIFRSMember451602024-04-012025-03-31jpigp_cor:RetainedEarningsIFRSMember451602024-04-012025-03-31jpigp_cor:TreasurySharesIFRSMember451602024-04-012025-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember451602024-04-012025-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602024-04-012025-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602024-04-012025-03-31jpigp_cor:RemeasurementsOfDefinedBenefitPlansIFRSMember451602024-04-012025-03-31jpigp_cor:NonControllingInterestsIFRSMember451602024-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602024-03-31jpigp_cor:ShareCapitalIFRSMember451602024-03-31jpigp_cor:CapitalSurplusIFRSMember451602024-03-31jpigp_cor:RetainedEarningsIFRSMember451602024-03-31jpigp_cor:TreasurySharesIFRSMember451602024-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember451602024-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602024-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602024-03-31jpigp_cor:RemeasurementsOfDefinedBenefitPlansIFRSMember451602024-03-31jpigp_cor:NonControllingInterestsIFRSMember451602023-04-012024-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602023-04-012024-03-31jpigp_cor:ShareCapitalIFRSMember451602025-03-31jpcrp_cor:ReportableSegmentsMember451602025-03-31tse-acediffr-45160:PharmaceuticalsMember451602025-03-31tse-acediffr-45160:FunctionalFoodMember451602025-03-31jpcrp_cor:ReconcilingItemsMember451602024-04-012025-03-31jpcrp_cor:ReportableSegmentsMember451602024-04-012025-03-31tse-acediffr-45160:PharmaceuticalsMember451602024-04-012025-03-31tse-acediffr-45160:FunctionalFoodMember451602024-04-012025-03-31jpcrp_cor:ReconcilingItemsMember451602024-03-31jpcrp_cor:ReportableSegmentsMember451602024-03-31tse-acediffr-45160:PharmaceuticalsMember451602024-03-31tse-acediffr-45160:FunctionalFoodMember451602024-03-31jpcrp_cor:ReconcilingItemsMember451602023-04-012024-03-31jpcrp_cor:ReportableSegmentsMember451602023-04-012024-03-31tse-acediffr-45160:PharmaceuticalsMember451602023-04-012024-03-31tse-acediffr-45160:FunctionalFoodMember451602023-04-012024-03-31jpcrp_cor:ReconcilingItemsMemberiso4217:JPYxbrli:sharesxbrli:pureiso4217:JPY